SystemManufacturing & Quality

The complete guide · November 2026

Validation document review, explained.

Before a medical device or medicine maker tests a machine, a process or a measuring method for the record, someone writes down what will count as a pass. Afterward, someone writes down what happened. Validation document review is the quality check on both papers: a qualified person reads them, marks what is wrong, and sends them back before they can be relied on.

This guide is for quality reviewers, validation engineers, quality assurance (QA) managers and document control staff at device, drug and biotech manufacturers. It also serves leaders deciding whether software should read alongside their reviewers. No background needed.

See one case, screen by screen →
Watch with transcript →
A quick example · fictional

Imagine you are a quality reviewer at a catheter maker's plant in Leiden. It is the morning of October 6, 2026. An engineer, Sam Patel, has sent you an 8-page protocol, TMV-0195. It describes how he will prove that a camera system, VM-05, can measure where a marker band sits on the Dravenzo 7F delivery catheter: 10.0 mm from the tip, give or take 0.3 mm. He wants to start measuring soon.

You read Table 2, the list of what will count as a pass. Gage error is how much the measuring itself wanders, and distinct categories is how many groups of parts the camera can tell apart. Then you open the standard operating procedure (SOP) that governs this kind of study, SOP-QA-0112, at revision D, page 6, section 6.2.

Sam's protocol, Table 2
Total gage error
at most 20% of tolerance
Operator bias
at most 5%
Distinct categories
nothing stated
SOP-QA-0112 rev D, section 6.2
Total gage error
at most 20% of tolerance
Distinct categories
at least 5, and reported
The protocol leaves out a limitThe procedure requires it before the study runsand the cover page shows why: Sam wrote on template revision D, replaced on July 1 by revision E, which added the table where that limit belongs.

Good review catches this today, when adding one row costs a minute. Found after the study, a limit written with the results in hand is hard to defend, and the study may have to run again.

Validation document review guide
Part A · Understand it

What a validation reviewer checks, which rule asks for it, and how to tell whether the check worked

What a reviewer looks for, which rules ask for it now that the US device rule has changed, how to work the statistics by hand, what inspectors write down, and why two careful people return different lists. No product is named here. If you are new to this work, start at the top.

01 · In plain words

A validation document is a promise and its proof, and review decides whether either one can be trusted

A factory wants to rely on something: a sealing machine, a sterilization cycle, a pull-force tester, a camera that measures a catheter. Regulators ask it to show, in writing, that the thing does its job. That showing is called validation, and it leaves two kinds of paper. A protocol is written first and says what will be done and what will count as a pass. A report is written afterward and says what happened and whether the pass was met.

Those papers carry a lot of small claims. This procedure applies, at this revision. This instrument was in calibration on those days. This requirement is covered by that test. These ten parts were chosen for a reason. This number on the data sheet was changed by this person, on this date, for this reason. Each claim points at some other controlled document or record, and a mistake in any of them can make the whole study hard to rely on.

So a second person checks. A quality reviewer opens the document beside the template, the procedures, the requirements, the calibration certificates and the raw data, and works through it page by page. She writes corrections, which people call redlines, and returns the document to its author. Only a document that survives this is approved. The check takes hours, it is hard to do well when five documents are waiting, and much of it is clerical work sitting right next to scientific judgment.

Two things make this work worth a whole guide. First, timing. A flaw caught in a protocol costs a sentence, and the same flaw caught in a report can cost a repeat study. Second, a review is itself a kind of measurement, and we found no published figure for how many defects reviewers miss. Both matter more now that software offers to read alongside human reviewers.

A validation document's path from draft to approved record, with two reviews on the way

  1. Write the protocolThe validation engineer writes tests and limits on the controlled template, against the requirements and procedures.
  2. Review before executionA quality reviewer checks the protocol. Limits, part selection and citations can all still change at no cost.
  3. Run the studyOperators follow the approved protocol and record results, which people call execution. Any significant change is written up as a deviation.
  4. Review the reportThe reviewer checks the report against the protocol, the raw data and the requirements.
  5. Approve and keepNamed people approve. The record stays available for inspection, and a later change can reopen it.

Steps 2 and 4 are the subject of this guide. The people, company and figures in the example are fictional.

What new validation reviewers rarely expect, from a date to look up to a score nobody publishes

The right revision depends on a date you must look up

Today's revision may be the wrong one to judge by. Many quality systems ask what was in force when the work was done, so a reviewer needs the effective date of every cited document and the first test date (section 5).

A number can pass and prove little

The same measuring tool can look capable or useless depending on which parts went into the study. Ten catheters from one lot can make a good camera fail one statistic, and a poor choice can hide a weak one (section 6).

The US device rule changed this year

In 21 CFR, FDA's rulebook, sections 820.30, 820.72 and 820.75 were familiar labels on device validation checklists. Since February 2, 2026 the rule runs on clauses of ISO 13485:2016, the international quality standard for device makers, and FDA's letters already cite them.1,2

Nobody publishes how good reviewers are

We found no public figure for agreement between validation reviewers, or for how many defects get past them. The nearest studies come from other fields, and they do not flatter human reviewers (section 10).

What protocol, acceptance criterion, redline and ndc mean in a review

Protocol

The pre-approved plan for a validation study: what will be done, on what, by whom, and what result counts as a pass.

Acceptance criterion

The limit a result must meet, stated before the study. Europe's good manufacturing practice rules (EU GMP) say "pre-defined acceptance criteria".3

Redline

A located correction: page, section, what is struck and what is proposed in its place. A finding is the defect behind one or more redlines.

ndc

Number of distinct categories: how many groups of parts a measuring method can tell apart. Five or more is the common expectation.4

Fourteen terms are defined in the one-page summary.

02 · What gets checked

IQ, OQ, PQ, test method and design verification documents: what a validation reviewer checks in each

In shortValidation is a family of documents, and each proves something different. The reviewer's questions stay fairly constant across them: is it on the right template, does it cite what was in force, does every requirement reach a test, were limits set first, can the raw data be trusted, and can a stranger read it.

DocumentWhat it provesWhat a reviewer leans on hardest
Installation qualification (IQ)The equipment is installed as drawn and specified, with instruments calibrated.3Drawings at the right revision, calibration, pre-defined criteria
Operational qualification (OQ)It works as designed, including upper and lower limits or worst cases.3Tests that reach the limits, expected results traced to a specification
Performance qualification (PQ)It performs in normal use, with production materials or a proven stand-in, under normal operating conditions.3Sampling, duration, conclusions the results support
Test method validation (TMV)A measurement can be trusted for its use. For drugs, the rule speaks of a method's accuracy, sensitivity, specificity and reproducibility.5Statistics recomputed from raw data, part selection, stated limits
Design verification (DV)A device design meets its input requirements, with methods, criteria and a reason for the sample size.6Requirements coverage, sample size, a conclusion matching the results
Process validation, or process performance qualification (PPQ)A manufacturing process consistently does what it should. FDA's drug guidance sets out what the protocol and report should hold.7Sampling plan, statistics, deviations, a clear conclusion
The same six questions run through every validation document, and limits set in advance weigh the most

How much weight each question usually carries in review. Our classification, drawn from the texts in this section. Your procedure may differ.

SomeHeavyDecisive
TemplateCitations in forceTracingLimits set firstRaw dataClear writingIQHeavyHeavySomeHeavyHeavySomeOQHeavyHeavyHeavyDecisiveHeavySomePQHeavyHeavyHeavyDecisiveHeavySomeTest method validationHeavyDecisiveHeavyDecisiveDecisiveSomeDesign verificationHeavyHeavyDecisiveDecisiveHeavySomeProcess validation reportHeavyHeavyHeavyDecisiveDecisiveSome

Our reading of the sources 3 7 5 6

Show the numbers
TemplateCitations in forceTracingLimits set firstRaw dataClear writing
IQHeavyHeavySomeHeavyHeavySome
OQHeavyHeavyHeavyDecisiveHeavySome
PQHeavyHeavyHeavyDecisiveHeavySome
Test method validationHeavyDecisiveHeavyDecisiveDecisiveSome
Design verificationHeavyHeavyDecisiveDecisiveHeavySome
Process validation reportHeavyHeavyHeavyDecisiveDecisiveSome

A validation protocol review and a validation report review ask different things

A protocol review asks whether the plan can succeed: are the limits complete and stated, are the parts and samples the right ones, is the original record named, is the template current. A report review asks whether the plan was followed and what it showed: does each criterion have a result, do the numbers recompute from the raw data, are corrections explained, were instruments in calibration on those dates, does the conclusion follow.

The same person often does both, and many defects in a report began as a gap in its protocol.

Software validation is a cousin. Computer system validation documents follow the same review logic, with their own rules. This guide uses physical test and equipment documents as its examples. Sizing software testing to risk has its own guide on this site, and writing qualification protocols has another.
03 · The rules, November 2026

Which rule asks for validation review now: Part 820 after the QMSR, Part 211, and EU GMP Annex 15 awaiting amendment

In shortNo rule says "use a validation document reviewer". The duty comes from rules that documents be approved by someone responsible, that criteria exist and that results be recorded. For US devices those rules, in 21 CFR Part 820, changed on February 2, 2026, when FDA's Quality Management System Regulation (QMSR) took effect. For US finished drugs they sit in Part 211. In Europe, Annex 15 of 2015, the EU GMP chapter on qualification and validation, applies, with a draft amendment due for consultation in December 2026 and publication planned for April 2028.8

The device rule has just changed, and the European Medicines Agency (EMA) timetable puts an amended Annex 15 in April 2028
  1. January 2011FDA process validation guidance

    Three-stage lifecycle for drugs and biologics. Nonbinding.

  2. October 1, 2015EU GMP Annex 15 in operation

    Still the version listed in November 2026.

  3. March 2024FDA issues ICH Q2(R2)

    Validation of analytical procedures, drugs.

  4. February 2, 2026QMSR takes effect

    ISO 13485:2016 by reference. FDA stops using QSIT, its old inspection technique.

  5. February 3, 2026FDA's Computer Software Assurance guidance reissued

    Device production and quality management system software.

  6. November 2027Endorsement planned

    By EMA's inspectors' group, on the same timetable.

  7. April 2028Amended Annex 15 planned

    Publication by the Commission and adoption by PIC/S, a cooperative group of medicine regulators focused on GMP.

Source 1 9 10 3 11 8 7 12

Show the numbers
WhenWhat
January 2011FDA process validation guidance
October 1, 2015EU GMP Annex 15 in operation
March 2024FDA issues ICH Q2(R2)
February 2, 2026QMSR takes effect
February 3, 2026FDA's Computer Software Assurance guidance reissued
December 2026Draft amended Annex 15 due
November 2027Endorsement planned
April 2028Amended Annex 15 planned

The old device labels and the clauses that replaced them

FDA's final rule calls the requirements of ISO 13485 substantially similar to the old ones. It incorporates ISO 13485:2016 by reference and reserves the old sections, which means it empties them, including 820.30, 820.40 and Subparts C to O, where 820.72 and 820.75 sat.9 Many checklists, templates and training slides still carry the old labels. A reviewer should know both, because records made before February 2026 use the old ones.

SubjectLabel until February 1, 2026Label now
Design verification21 CFR 820.30(f)ISO 13485:2016 clause 7.3.6
Design validation21 CFR 820.30(g)Clause 7.3.7
Process validation21 CFR 820.75Clause 7.5.6
Monitoring and measuring equipment21 CFR 820.72Clause 7.6
Document control21 CFR 820.40Clause 4.2.4, with records under 4.2.5

The mapping is our reading of 89 FR 7496, the clause table in FDA's inspection program and FDA's letters.9,13,2,14 ISO sells its text, so we read summaries and FDA's wording.6

What each text says about review, limits and records

TextReachWhat it says
ISO 13485:2016, through Part 820US devices, and widely elsewhereVerification and validation plans with methods, acceptance criteria and a rationale for sample size.14,6
21 CFR 211.100(a)US finished drugsProcess control procedures, with changes, "drafted, reviewed, and approved" by the right units and by the quality control unit.15
21 CFR 211.165(e) and 211.194(a)(2)US finished drugsAccuracy, sensitivity, specificity and reproducibility of test methods "established and documented", with the location of the data.5,16
FDA process validation guidanceUS drugs and biologics; nonbindingExecution "should not begin until the protocol has been reviewed and approved by all appropriate departments, including the quality unit".7
EU GMP Annex 15EU medicinesDocuments "approved and authorised by appropriate personnel". Protocols define "the associated acceptance criteria". Results summarized against the acceptance criteria.3
Status check, November 3, 2026. EudraLex Volume 4 lists Annex 15 as in operation since October 1, 2015.11 EMA's concept paper sets the timetable in the chart above for a targeted revision, which would make the annex mandatory for active substance manufacturers and reflect ICH Q9(R1), the international guideline on quality risk management.8 These are planned dates, and we found no draft as of November 3, 2026. An earlier work plan's Q4 2026 target for Annex 15 is overtaken. Plan for a change, and keep working to the current text.
04 · Before and after execution

Why acceptance criteria must be fixed before the study: what EU GMP and FDA say about a limit set late

In shortA limit stated before measuring is a test. A limit stated after measuring can be drawn around the result, whatever anyone intended. That is why protocol review has the highest return in this work: everything found there is cheap, and several defects can only be fixed there.

Annex 15 speaks of "pre-defined acceptance criteria" and says results that miss them "should be recorded as a deviation and be fully investigated". It adds that "any significant changes to the approved protocol during execution, e.g. acceptance criteria" should be documented as a deviation and "scientifically justified".3 A later change to a limit is possible, then, and it carries a burden of proof. FDA's drug guidance says the protocol's departures must be "justified and approved" by the appropriate departments and the quality unit "before implementation".7

A validation document meets a reviewer twice, and the second read depends on the first
  1. 1Draft protocol

    Tests, limits, parts and records, on the current template.

    Validation engineerCheapest to fix
  2. 2Protocol review

    Limits complete? Parts chosen on purpose? Original record named?

    Quality reviewerA sentence
  3. 3Approved, then executed

    Changes become deviations, with a scientific reason.

    Operators and engineerA deviation
  4. 4Report review

    Results against each limit, raw data, corrections, calibration.

    Quality reviewerA correction, or a new test
  5. 5Approved report

    Later findings reopen it, and may reach an inspector.

    Quality approverA repeat study, or worse

Our reading of the sources 3 7

Show the numbers
StepWhat happensWhoTime
Draft protocolTests, limits, parts and records, on the current template.Validation engineerCheapest to fix
Protocol reviewLimits complete? Parts chosen on purpose? Original record named?Quality reviewerA sentence
Approved, then executedChanges become deviations, with a scientific reason.Operators and engineerA deviation
Report reviewResults against each limit, raw data, corrections, calibration.Quality reviewerA correction, or a new test
Approved reportLater findings reopen it, and may reach an inspector.Quality approverA repeat study, or worse

What the same defect costs, depending on when a reviewer finds it

DefectFound in the protocolFound in the reportFound by an inspector
A required limit is missingAdd a rowA limit set after the data, with a justification, or a repeatA written observation, and questions about other studies
Parts do not span the rangeChange the selectionThe statistic may fail, so repeat with new partsDoubt about whether the method was ever shown fit
Superseded procedure citedUpdate the citation and check what changedShow the work met the revision in force, or test againA document control question that widens
Readings copied by hand with no original namedName the export as the originalReconcile paper against the system, if it kept the dataA data integrity question

This is our reasoning from the texts above, with no published outcomes behind it. We found no public figure for the cost of a repeated validation study. Section 18 shows how to find yours.

A limit can be added late, honestly. Sometimes a criterion was forgotten, and the data are sound. Say so in the report: what was missed, when it was noticed, why this limit, and whether anyone had seen results first. What damages trust is a limit that appears with no story attached.
05 · The revision in force

Which revision governs: checking every citation against its effective date and the first test date

In shortEach controlled document has revisions with effective dates, and a validation cites some of them. The reviewer asks which revision was in force when the work was done. ISO 13485 requires control of documents, and Part 211 requires that procedures and their changes be reviewed and approved.13,15 The specific test, "in force on the first test date", is a quality system's own rule, and a sensible one to write down.

Take the report in this guide's example, TMV-0193. It cites SOP-QA-0112 at revision C. Revision D took effect on June 15, 2026. The pull tests ran August 18 to 20. So the procedure the report names no longer governed the work when it was done, and the change was substantive: revision C allowed total gage error up to 30% of the tolerance and said distinct categories "may be recorded for information". Revision D set 20% and required at least five categories, reported.

Revision D took effect nine weeks before the tests, so the report's citation of revision C is out of date

TMV-0193 in the guide's fictional example.

  1. February 3, 2025SOP-QA-0112 revision C effective

    Total gage error up to 30%; ndc optional.

  2. June 15, 2026Revision D effective

    Total gage error up to 20%; ndc at least 5, reported.

  3. July 1, 2026Templates revised

    TPL-TMV-001 revision E adds the criteria table.

  4. August 18 to 20, 2026Pull tests run

    First test date: August 18.

  5. October 6, 2026Report reaches the reviewer

    Cites revision C on page 2.

Fictional example from this guide

Show the numbers
WhenWhat
February 3, 2025SOP-QA-0112 revision C effective
June 15, 2026Revision D effective
July 1, 2026Templates revised
August 18 to 20, 2026Pull tests run
October 6, 2026Report reaches the reviewer

Four date questions a good reviewer settles before judging a citation

  1. Which date counts? Comparing the effective date with the first test date is common, and some companies use the protocol's approval date instead. Whichever you choose, write it into a procedure, since we found no regulator that sets one.
  2. What changed between revisions? A renumbered annex and a tightened limit are different problems. The right response to the first is a correction, and to the second a look at whether the work meets the new limit.
  3. Was there a transition period? Many procedures allow studies already under way to finish under the old revision. The citation may then be right, and it needs a sentence saying so.
  4. Is the library itself current? External standards change on someone else's schedule. A company's standards register can lag, and a reviewer who trusts it inherits the lag. ISO 10555-1, for catheters, moved to a 2023 edition replacing the 2013 edition and its 2017 amendment.17
Document control drew 64 citations on device Form 483s in fiscal 2025, and only 2 name unapproved or obsolete documents where they could be used

A Form 483 lists what an FDA investigator observed at an inspection. Citations under 820.40 by subject, our sums of FDA's rows, the last full year under the old labels. FDA's file does not explain each one.

Procedures not established or kept42
Review and approval before issue13
Records and approval of changes7
Unapproved or obsolete documents where they could be used2

Source 18

Show the numbers
ItemValue
Procedures not established or kept42
Review and approval before issue13
Records and approval of changes7
Unapproved or obsolete documents where they could be used2

The four parts add up to 64, by FDA's cite IDs: 14722 and 447; 454, 3199 and 3838; 3203, 3204 and 3198; and 3201. An old citation inside a validation report would normally be cited under a broader row, so a low count on one line says little about how common it is.

06 · Gage R&R, ndc and sample size

Gage R&R and ndc worked through by hand, and why ten parts from one lot can fail a good camera

In shortA test method validation asks how much of what you measure is the part and how much is the measuring. Reviewers recompute the answer from the study's own numbers. Two statistics matter most: gage error as a share of the tolerance, the allowed range, and the number of distinct categories. The second depends on the parts chosen, so the protocol must choose them on purpose.

In a gage R&R study, several operators measure the same parts several times. The variation splits into repeatability (the same operator, the same part, a different reading), reproducibility (different operators) and part variation (the parts themselves differ). Repeatability and reproducibility together are the gage error, written GRR.

These terms come from the AIAG Measurement Systems Analysis manual, an automotive industry text many device makers adopt in their own procedures. It becomes binding on a company only through that company's procedure. Minitab, a statistics software maker, reports its guideline of under 10% of process variation as acceptable, and its recommendation of five or more categories.4,19 A limit such as 20% of the tolerance is a company's own, written into its procedure.

The arithmetic on the fictional pull-force report

StepCalculation, from TMV-0193 Table 3Result
Gage error from its two parts√(0.170² + 0.111²) in newtons0.203 N
Total variation√(0.203² + 1.051²), with part variation at 1.051 N1.070 N
Gage error as a share of study variation0.203 ÷ 1.07019.0%
Distinct categories1.41 × (1.051 ÷ 0.203) = 7.3, truncated4ndc = 7

The report printed all of that except the last line, and its procedure requires the last line. A reviewer who recomputes finds the method probably passes, and still sends it back, because a criterion with no reported result cannot be shown as met. She would also ask about the sample report's 14.1% of tolerance: the requirement has only a lower limit, at least 15.0 N, so the tolerance behind that percentage has to be stated somewhere.

Why the protocol must say how parts are chosen

The formula divides part variation by gage error. So ndc rises when parts differ more, with the measuring tool unchanged. Try it on the example's marker band, with a tolerance of ±0.3 mm, a span of 0.6 mm. Suppose the camera's gage error is 0.02 mm. Six times that is 0.12 mm, exactly 20% of the tolerance, so it sits at the limit in Table 2. Now pick the parts.

The same camera scores ndc 2 on parts from one lot and ndc 14 on parts chosen across the tolerance

Gage error fixed at 0.02 mm. ndc = 1.41 × part standard deviation ÷ gage error, truncated. Part spreads are our assumptions: 0.03 mm for one lot, 0.20 mm for ten parts spaced evenly from 9.7 to 10.3 mm.

Ten parts at random from one lot2
Parts just wide enough to reach the limit (0.08 mm)5
Ten parts spaced across 9.7 to 10.3 mm14

Illustrative · replace with your own numbers

Show the numbers
ItemValue
Ten parts at random from one lot2
Parts just wide enough to reach the limit (0.08 mm)5
Ten parts spaced across 9.7 to 10.3 mm14

That is the point of the finding about part selection in the example. Taken at random from a single lot, the parts cluster, and a good camera looks unable to tell them apart. A reviewer who sees "at random from lot 26-0412" in a protocol can spare the engineer a failed study. The same logic works the other way: parts chosen too far apart can flatter a weak method. So the reviewer asks that the choice be stated, and match the range the method will meet in use.

Sample size: the reviewer's second piece of arithmetic

Design verification often proves a requirement by testing some units with no failures. The usual formula, the success run theorem, is n = ln(1 − C) ÷ ln(R), for confidence C (how sure you want to be) and reliability R (the share of units that must work).20 A reviewer checks that the stated sample size matches the stated confidence and that the reason for choosing that confidence appears, often through the requirement's risk. FDA has cited a firm whose validation plans lacked a "rationale for sample size" (section 9).14

Each step up in reliability costs far more units: 29, then 59, then 299 with no failures allowed

Units needed at 95% confidence and zero failures, rounded up. Our arithmetic from the formula.

2990% reliability
5995% reliability
29999% reliability

Source 20

Show the numbers
PeriodValue
90% reliability29
95% reliability59
99% reliability299
A trap in the same sum. The formula holds only with zero failures. If one unit fails, you cannot simply restate the claim, and changing the confidence level after a failure is poor practice.20 A report that claims 95% confidence and 90% reliability, often written 95/90, and shows a failed unit anywhere in its raw data deserves a hard look.
07 · Traceability both ways

Reading a requirements traceability matrix both ways, so an untested requirement and an orphan test both surface

In shortTraceability links each requirement to a test and a result. Read it forward and you find requirements nobody tested. Read it backward and you find tests that prove nothing anyone asked for. A rule that says a method covers a condition is also a requirement, and those are the ones that get lost.

The example's report shows how this slips. The product specification says tip-to-shaft pull force must reach at least 15.0 N after two hours soaking at 37 °C, because that is how the catheter is used. The test method's own scope lists hydrated catheters. A water bath is listed in the equipment table. And section 7.1 of the report covers three other requirements and stops. Nobody lied, and every page looks finished. A reader has to hold three documents at once to see that the hydrated condition was never tested.

Six of eight requirements trace cleanly in the sample report, and the two that do not are the ones that matter

TMV-0193 traceability, from the product specification, the test method and the governing procedure.

Traced to a test and a resultCriterion but no resultNo test
TMV-0193611

Fictional example from this guide

Show the numbers
Traced to a test and a resultCriterion but no resultNo test
TMV-0193611

What each direction of the trace catches

Read this wayQuestionWhat it finds
Requirement to testDoes every requirement reach a test with a recorded result?Conditions never tested, such as hydrated, aged or sterilized
Test to requirementDoes every test answer a stated requirement?Effort spent on nothing, or a requirement that was removed
Procedure to criterionDoes each thing the procedure demands appear as a limit?A statistic required by the procedure and absent from the protocol
Criterion to resultDoes each limit have a number in the results and a word in the conclusion?A limit stated and never reported, like ndc in the example
Equipment to testIs each instrument used, and each one used listed?A water bath listed and never used: a hint of a missing test
08 · Records and calibration

ALCOA in a validation report: corrections, hand-copied readings, original records and calibration on the test date

In shortA reviewer treats raw data as evidence, and FDA's ALCOA test says what good evidence looks like. On a validation document that comes down to four things to look for: who changed what, whether the reading in the report matches where it was first captured, whether that first capture still exists, and whether the instrument was in calibration that day.

FDA's 2018 guidance sets out the expectation: data "attributable, legible, contemporaneously recorded, original or a true copy, and accurate (ALCOA)".21 It compares audit trail review, the check of a system's own log of who changed what, to "assessing cross-outs on paper".21 MHRA, the UK medicines regulator, notes that the plus in ALCOA+ refers to complete, consistent, enduring and available, and says there is no difference in expectations.22

PIC/S describes the original record as "the first-capture of information".23 That phrase decides the example's finding on results copied by hand: the camera holds images and results with an audit trail, and the protocol tells operators to write readings onto paper. MHRA recognizes hybrid records of paper and electronic data, so this is a choice to make on purpose, and the protocol should name which record is the original.22

Copying readings onto paper leaves the most for a reviewer to chase, because attribution and the first capture have split apart

How much a reviewer must check per ALCOA+ quality, for three ways of recording one reading. Our judgment, from the guidance cited.

Built inCheck itChase it
AttributableLegibleAt the timeOriginalAccurateCompleteSystem export with audit trailBuilt inBuilt inBuilt inBuilt inCheck itCheck itWritten directly on a controlled data sheetCheck itCheck itCheck itBuilt inCheck itCheck itRead from a screen, copied onto paperCheck itCheck itCheck itChase itChase itChase it

Our reading of the sources 21 22 23

Show the numbers
AttributableLegibleAt the timeOriginalAccurateComplete
System export with audit trailBuilt inBuilt inBuilt inBuilt inCheck itCheck it
Written directly on a controlled data sheetCheck itCheck itCheck itBuilt inCheck itCheck it
Read from a screen, copied onto paperCheck itCheck itCheck itChase itChase itChase it

Four things on a data sheet that a reviewer stops at

Look forWhySample case
A correction with no initials, date or reasonThe old value must stay legible, and the person and reason must be known. Companies write this into a documentation procedure.Trial 2 of sample S07 struck from 21.4 N to 20.4 N, with nothing else
An ID written two waysAn instrument link breaks, and so does the link to its calibration record.Load cell LC-2270 in one section, LC-2207 everywhere else
A blank calibration due dateDrug rules ask for calibration at suitable intervals, and ISO 13485 clause 7.6 covers device measuring equipment.24,2 A blank means a reader cannot confirm it.Load cell LC-2207, with certificate on file, due March 9, 2027
A date a stranger could misreadMany sites write DD-MMM-YYYY so 8/19/26 cannot be misread across countries. That is a company rule, and a reviewer enforces the one in force.Data sheet dated 8/19/26 at a site whose procedure asks for 19-Aug-2026
09 · What inspectors cite

What FDA cites in validation work: process validation rows on Form 483s, and letters under the new device rule

In shortProcess validation was cited 153 times in fiscal 2025 on device Form 483s, the lists of observations FDA investigators leave after an inspection, by our sum of FDA's rows. FDA's letters show what lies behind such rows: no test method validation, no raw data, no pass or fail criteria, no sample size rationale. FDA's newest device letters cite ISO 13485 clauses. The rows cannot say how many defects a document review would have caught.

Per 100 device Form 483s, process validation citations stay between 16 and 23, and measuring equipment citations fall to about 5

Citations per 100 device Form 483s, our sums of FDA's rows over FDA's count of forms: 966, 822, 422, 191, 538, 720, 672 and 791. Fiscal 2025 counts are 153, 64 and 41. Raw counts dropped in fiscal 2020 and 2021 with the number of forms. All predate the QMSR.

Process validation (820.75)Document control (820.40)Measuring equipment (820.72)
010203019.38.15.2
FY18FY19FY20FY21FY22FY23FY24FY25

Source 18

Show the numbers
Process validation (820.75)Document control (820.40)Measuring equipment (820.72)
FY1821.58.410.4
FY1921.813.79.5
FY2018.515.410
FY2118.3126.8
FY2222.911.39.7
FY2316.17.99.9
FY2418.57.78.2
FY2519.38.15.2
Process validation and design validation lead the validation-related rows on device Form 483s

Fiscal 2025 citations by section, our sums, across 791 device Form 483s in FDA's file. Forms can hold several citations.

Process validation (820.75)153
Design validation (820.30(g))115
Document control (820.40)64
Measuring equipment (820.72)41
Statistical techniques (820.250)32
Design verification (820.30(f))24

Source 18

Show the numbers
ItemValue
Process validation (820.75)153
Design validation (820.30(g))115
Document control (820.40)64
Measuring equipment (820.72)41
Statistical techniques (820.250)32
Design verification (820.30(f))24
93

device citations in fiscal 2025 for a process validated inadequately or not at all, by the largest single row.18

FDA data, cite ID 546
21

device citations for validation results or activities not adequately documented or approved.18

FDA data, cite ID 3118
23

drug citations under 21 CFR 211.165(e), on the accuracy and reproducibility of test methods.18,5

FDA data, cite ID 1890

Five FDA letters and what each says about validation paperwork

LetterWhat FDA wroteWhat a document review would ask
Linemaster Switch, May 27, 2026, clause 7.62A software validation "did not include: Raw data from validation testing", "Pass/fail criteria or results", "Statistical analysis or sample size rationale".Is there a limit, a result and a reason for each one?
Unilam, September 22, 2026, clause 7.3.114No "validation plans that include methods, acceptance criteria, rationale for sample size, rationale for choice of product".Does the plan exist before the test, with its reasons?
Microspecialties, May 8, 202525Refers to "the lack of test method validation for the seal integrity inspection" and sampling without statistical support.Was the inspection method itself shown fit?
Caltag Medsystems, August 31, 202326Protocols "should contain or refer to objective and measurable acceptance criteria" and describe the statistical method.Could two people agree whether this limit was met?
Tower Laboratories, December 23, 202527A drug letter in which the firm acknowledges that it did not fully meet test method validation requirements, and FDA finds the response inadequate.Does the validation cover what this method is used for?

Each letter concerns one firm, usually with other findings. They show the kind of gap FDA writes down, and imply nothing about frequency. These firms were chosen for what the letters say.

Reading these numbers honestly. FDA's file counts citations by rule and carries no explanation. Some Form 483s were prepared by hand and are not in it.18 Only one row, with a frequency of 1, says acceptance criteria were not established before validation, and a missing limit would more often sit under broader rows. So these figures show how much attention validation gets from inspectors, and they leave open how often a review misses something.
10 · Why reviewers differ

Why two good quality reviewers return different findings, and how overlap estimates what both missed

In shortWe found no study of agreement between validation reviewers. Other fields measure it, and agreement is modest. Software engineering has studied better ways of reading for 30 years: readers assigned different perspectives cover more of a document than the same number using their usual approach. The overlap between readers can also estimate what everyone missed.

.34

mean intraclass correlation for reviewers judging the same journal manuscript, across 48 studies and 19,443 manuscripts. Mean Cohen's kappa was .17.28

Other field: journal peer review
41%

more unique defects found by teams reading from assigned perspectives than by checklist teams, with 18 practitioners.29

Other field: software design documents
58%

of the known defects found on average by those perspective teams, so teams still missed a lot.29

Same experiment

Those numbers come from elsewhere, and they do not transfer directly. A journal referee gives an opinion on whole papers, and a validation reviewer checks facts against a template. Intraclass correlation and kappa both reach 1 at perfect agreement, so .34 and .17 sit far from it. What carries over is the structure. A person reading for everything at once tends to catch what they are best at and what they saw first.

In a controlled experiment at NASA's Software Engineering Laboratory, teams reading from assigned points of view such as tester, developer and user achieved "significantly better coverage" than teams using their usual approach.30 A later replication against checklists pointed the same way, with one exception: on the one document where two perspectives found similar defects, perspective readers were no more effective. The authors offered complementary perspectives as a new hypothesis.31

From reading for everything to reading from one angle

AngleReads asCatchesMisses
ProcedureA quality auditorOld revisions, wrong template, missing sectionsWhether the test design works
DataA forensic readerCorrections, hand copies, calibrationWhether the right thing was measured
Test designA statistician and engineerParts, samples, limits, recomputed numbersClerical slips that do not affect a result
LanguageA stranger, years laterUndefined terms, two versions of an ID, numberingAnything that reads well and is wrong

What overlap tells you: the capture-recapture estimate

Biologists estimate a fish population by marking a catch and counting marks in a second catch. Software inspection borrowed the method in 1992 to estimate defects left after a review.32 The arithmetic is short. Reviewer A finds 12 defects, B finds 10, and 6 are the same. If B caught 6 of A's 12, that is half, so B probably catches about half of everything. Then the total is about 12 × 10 ÷ 6 = 20. Together they found 16, so about 4 remain.

Two reviewers who share 6 of their findings have probably left about 4 unseen

Lincoln-Petersen estimate on made-up numbers: total = A × B ÷ shared. Replace with two of your own reviewers on one document.

Reviewer A found12
Reviewer B found10
Together, without double counting16
Estimated total defects20

Illustrative · replace with your own numbers

Show the numbers
ItemValue
Reviewer A found12
Reviewer B found10
Together, without double counting16
Estimated total defects20
Use this as a prompt, and keep the limits in view. The method assumes readers are independent and defects equally easy to find. A 1995 experiment found those assumptions are not fully met, which leads to underestimates.33 Readers assigned different angles deliberately break the first assumption. Try it on a few documents to learn roughly how much gets past your team, and treat the answer as a floor.
11 · Scoring a reviewer

How to score any validation reviewer: recall, false alarms and an answer key, with the arithmetic on 63 critical findings

In shortTake past documents, collect what your reviewers found and signed, and treat that as an answer key. Recall says how much of the key a new reviewer finds. The false-alarm rate says how much of what it raises is unsupported. Both have real limits: small numbers leave wide uncertainty, and the key itself contains human misses.

The four counts behind every accuracy claim

The answer key has itThe answer key lacks it
The reviewer raised itHit. Counts toward recall.Either a false alarm or a real defect that past reviewers missed. Someone must look.
The reviewer did not raise itMiss. The count that matters most.Not counted, and unknown by definition.
  • Recall = hits ÷ everything in the key. Report it by severity, because finding every comma and missing a critical is a bad review.
  • False-alarm rate, as used here, = raised and not upheld ÷ everything raised. Statisticians call this the false discovery rate, and it differs from a false-positive rate. Ask which one a vendor means.

How sure can you be of a high score on 63 criticals

Take a score of 61 critical findings out of 63, or 96.8%. It sounds precise. An exact 95% confidence interval, the range where the true score plausibly sits, runs from 89.0% to 99.6% for that count, by our calculation with the standard method for a proportion.34 Each single miss moves the score by 1.6 points.

Two more misses in 63 cross a 95% limit, and even 61 of 63 cannot rule out a true score near 89%

Observed recall and the low end of its exact 95% interval. Our arithmetic. A 95% limit on a key this size is a useful alarm, and it cannot prove the true rate.

96.8%61 of 63 observed
95.2%60 of 63 observed
93.7%59 of 63 observed
92.1%58 of 63 observed
89%61 of 63, low end

Our reading of the sources 34

Show the numbers
PeriodValue
61 of 63 observed96.8%
60 of 63 observed95.2%
59 of 63 observed93.7%
58 of 63 observed92.1%
61 of 63, low end89%

Four ways an answer key can flatter or mislead

The key holds human misses

A true defect your past reviewer overlooked counts against the new reader as a false alarm. Recheck a sample of those by hand. Some will be real, which is useful to know.

Tuning on the test

If rules are adjusted until the score rises on the same documents, the score stops predicting new ones. Keep some documents aside, unseen, the way draft EU text asks that test data be kept independent for AI models in critical GMP uses.35

The key ages

Reviews closed under old procedures embed old rules. A new revision can make a past "pass" wrong by today's standard. Date the key, and refresh it deliberately.

Averages hide document types

A high overall score can conceal weak recall on one type, such as design verification, where only a few past reviews exist. Break the score down, and report how many documents sit behind each figure.

12 · AI in validation review

What regulators say about AI reading GxP documents, and where a large language model fits in validation review

In shortGxP means the good-practice rules for manufacturing, labs and trials. We found no rule that bans a tool from reading a validation document and flagging what it sees. Draft EU GMP Annex 22, the proposed chapter on AI, would keep large language models (LLMs) out of critical GMP uses, and that wording is under debate. For devices, FDA's Computer Software Assurance guidance reaches AI tools used in the quality management system. Where these texts speak to it, a qualified person stays responsible and the company assesses its own use. The practical risks are misses nobody sees and too much trust in the tool.

AI rules for this work are drafts, principles and one sharp warning letter, and draft Annex 22's wording is still under debate
  1. September 9, 2024EMA reflection paper

    Adopted by EMA's human medicines committee.

  2. January 2025FDA draft on AI for drugs

    Regulatory decision-making; still a draft.

  3. July 2025GAMP AI guide; draft Annex 22 opens

    Consultation closes October 7, 2025.

  4. January 14, 2026EMA and FDA joint principles

    Ten principles across a medicine's life, manufacturing included.

  5. February 3, 2026FDA's Computer Software Assurance guidance names AI tools

    Device production and quality management systems.

  6. April 2, 2026Warning letter on AI documents

    One firm, with other findings.

  7. June 30, 2026EMA workshop on Annex 22

    Comments favored allowing such models. No revised text.

Source 10 36 35 37 38 39 40 41 42 43

Show the numbers
WhenWhat
September 9, 2024EMA reflection paper
January 2025FDA draft on AI for drugs
July 2025GAMP AI guide; draft Annex 22 opens
January 14, 2026EMA and FDA joint principles
February 3, 2026FDA's Computer Software Assurance guidance names AI tools
April 2, 2026Warning letter on AI documents
June 30, 2026EMA workshop on Annex 22
August 2, 2028EU AI Act rules for AI in products

What each text means for a tool that reads validation documents

TextWhat it saysWhat it means here
FDA Computer Software Assurance guidance, February 2026The approach can apply to "artificial intelligence/machine learning tools" used "as part of production or the quality management system".10A device maker's review tool, used in its quality management system, falls within this approach. In one FDA example, a qualified person's later check makes an automated feature not high process risk.10 The company decides.
Draft EU Annex 22, 2025Generative AI and LLMs "should not be used in critical GMP applications". In non-critical uses, trained people "should always be responsible" for outputs.35A draft, with no force yet. It calls a use non-critical when it has no "direct impact on patient safety, product quality or data integrity".35 Whether a reading aid meets that is your own assessment. It covers medicines GMP, so a device maker reads it as a signal.
EMA workshop report, 2026Comments supported allowing LLMs, in critical or non-critical uses. The drafting group has discussed widening scope under a documented, risk-based control strategy, and concerns remain. "There may be viable pathways".37The line may move. No revised text is published.
FDA warning letter, April 2026"If you use AI as an aid in document creation, you must review the AI generated documents".36One firm's letter, and no general policy. The same logic fits review notes: a person answers for the result.
FDA AI draft, January 2025Its scope excludes operational efficiencies with no effect on patient safety, drug quality or study reliability.38Still a draft. Do not assume a review tool falls outside it without thinking it through.
EU AI Act after the AI OmnibusThe AI Omnibus, Regulation (EU) 2026/1744, sets Annex III rules from December 2, 2027 and Annex I product rules from August 2, 2028.41Check with counsel. A document review aid is unlikely to be the Annex I case, and this is our reading.
Software earns its place on mechanical checks with costly misses, and judgment on study design stays with people

Our reading of each kind of check, placed for reasoning. Positions carry no measured value.

What a miss can cost →
People lead; software prompts
Automate first, person confirms
People, when time allows
Automate freely
Is this test design sound?Conclusion follows resultsRevision on test dateLimit missing vs SOPRecompute statisticsCalibration dateCorrection initialsNumbering, terms
How mechanical the check is →

Our reading of the sources 10 35 44

Show the numbers
ItemHow mechanical the check is (0–1)What a miss can cost (0–1)
Is this test design sound?0.140.76
Conclusion follows results0.300.66
Revision on test date0.740.64
Limit missing vs SOP0.620.78
Recompute statistics0.780.56
Calibration date0.700.33
Correction initials0.560.28
Numbering, terms0.800.12

The risk nobody sees: a reviewer reads less because the tool read first

A person who decides each flagged item catches false alarms, and sees nothing of what the tool missed. If a reviewer stops reading the document and reads only the flags, the tool's misses become the review's misses.

A systematic review found automation bias, the tendency to over-rely on automation, is real and is shaped by trust, workload and time pressure, and that accountability, training and how advice is presented can reduce it.44 Those studies mostly concern clinical decision support, so treat them as a warning. Design the review so that a person still reads the parts that matter, sample some unflagged pages, and plant a known defect now and then to see whether people notice.

13 · How teams do it today

Who reviews validation documents today, where a sample reviewer's 3.5 hours go, and the public numbers that do not exist

In shortA validation document can pass through four or five people and return to its author more than once. The hours go to clerical checks more than to judgment, by one fictional team's estimate. Almost nothing in this work has a public benchmark, so your own stopwatch is the only credible baseline.

The author, the reviewer, the quality manager, document control and metrology

Typical roles, by description
VE

Validation engineer

Writes the protocol, runs or supervises the study, and writes the report.

Cares about: learning what to fix before measuring.
QR

Quality reviewer

Reads each document against the template, the library and the raw data, and returns it with redlines.

Cares about: a clear list, without spending the morning on calibration dates.
QM

Quality manager

Owns grading rules and who reviews what, and answers to the inspector.

Cares about: consistency across reviewers and plants.
DC

Document control

Keeps controlled documents, revisions and effective dates.

Cares about: a revision being current on the test date, whatever today's date is.
MT

Metrology

Holds calibration certificates and due dates for every instrument.

Cares about: instruments used only while in calibration.
A document can change hands five times, and each return to the author restarts the wait

A typical path. Timings vary widely, and we found no public benchmark.

  1. 1Author submits

    Word or PDF, into the document system or by email.

    Validation engineerStart
  2. 2Waits in a queue

    Alongside other documents and due dates.

    Quality reviewerHand-off 1
  3. 3Read against the library

    Template, citations, trace, statistics, raw data.

    Quality reviewerHours
  4. 4Redlines returned

    Comments, tracked changes, a findings list.

    Back to authorHand-off 2
  5. 5Corrected and approved

    Possibly more rounds, then named approvals.

    Author, reviewer, QAHand-offs 3 to 5

Illustrative · replace with your own numbers

Show the numbers
StepWhat happensWhoTime
Author submitsWord or PDF, into the document system or by email.Validation engineerStart
Waits in a queueAlongside other documents and due dates.Quality reviewerHand-off 1
Read against the libraryTemplate, citations, trace, statistics, raw data.Quality reviewerHours
Redlines returnedComments, tracked changes, a findings list.Back to authorHand-off 2
Corrected and approvedPossibly more rounds, then named approvals.Author, reviewer, QAHand-offs 3 to 5
Tracing and recomputing take the largest share of 3.5 hours, and clerical checks take most of the rest

Hours on one test method validation report reviewed by hand. One fictional team's estimate, in place of a measured benchmark.

Template sections and fieldsCitations at the test dateTracing and recomputingData sheets and calibrationTerms, numbering and write-up
One TMV report0.75 hours0.75 hours1 hour0.5 hours0.5 hours

Illustrative · replace with your own numbers

Show the numbers
Template sections and fieldsCitations at the test dateTracing and recomputingData sheets and calibrationTerms, numbering and write-up
One TMV report0.75 hours0.75 hours1 hour0.5 hours0.5 hours

Four ways teams run validation review today

WayStrengthWeakness
Word, PDF and a document systemCheap to start, and familiar. Reviewers keep full control.Every check is manual. Citations are looked up by hand.
A digital validation systemStructured protocols, enforced fields, built-in execution and trace.Needs everything authored inside it, and judgment about content remains manual.
An outside consultancy or second reviewerExtra capacity and independent eyes at peaks.Cost per document, with knowledge of your library leaving at the end.
Software reading alongside peopleMechanical checks done on every document, every time.New, with little public evidence. You must measure and assess it yourself.

The few public numbers, and the many that do not exist

About 39 in 100 respondents use or are evaluating AI for validation work, by one vendor's 2026 survey
39 in 100

of 614 validation professionals, using or evaluating AI for validation. A validation software vendor's survey, published as sponsored content.

Source 45

Show the numbers
MeasureValue
of 614 validation professionals, using or evaluating AI for validation. A validation software vendor's survey, published as sponsored content.39 of 100
What we looked for and did not find, as of November 2026. Hours per validation review. Agreement between validation reviewers. Rates of defects that get past review. The cost of a repeat study. A market size for review software. An independent measurement of any AI review tool's recall. Vendor statements such as "weeks to hours" come with no method, so we left them out. For scale, FDA reports 1,248 drug quality inspections in fiscal 2025, and its file shows 791 device Form 483s.46,18
Part B · See it working

One catheter protocol in Botminds Validation Document Review: read by four reviewers, decided by one person, back with its author

Part A described the work without naming a product. This part shows how Botminds does it for the protocol at the top of the page. The reviewers in its columns are software: four AI agents, programs that each read from one angle. The person who decides is the quality reviewer. Every person, product, plant, document and figure on the screens is sample data. The reviewers flag, a person decides, and Botminds never validates anything on your behalf: you validate your processes, and your use of this software.

14 · One protocol, start to finish

TMV-0195 on October 6: seven findings from eleven redlines, the missing ndc limit raised twice, and back to Sam before he measures

In shortSam Patel submits an 8-page protocol. It is read on arrival, then four AI reviewers read it separately, each from its own angle, and fill their own columns. Two of them flag the same missing limit. Dana Okafor, the quality reviewer, opens each finding with the procedure behind it, accepts it or dismisses it, and returns the document with a redlined copy. The software can never approve.

About the dates on these screens. We show them the US way here. The sample company's documentation procedure asks for DD-MMM-YYYY in its records, so the one correction that enforces that rule keeps its form. Your own rule goes in your settings.
1

Before Sam's protocol, the report on Dana's desk

Dana's review panel, the screen where the four AI reviewers report, is open on TMV-0193, an 11-page test method validation report for tip-to-shaft pull force on the Dravenzo 7F catheter. Four columns hold each reviewer's own located redlines: severity, page, section, and a strike-and-insert edit. A strip across the top shows the panel's score against 36 past reviews from sample data, and each column shows its own.

The review panel. Each reviewer in its own column. Seven of 11 findings were raised by two or more, each marked in every column that raised it. Figures are sample data.
2

An 8-page protocol, read on arrival

Sam's file arrives as a Word document. Before anyone reads it for defects, the software identifies the document and shows its confidence beside each line: a test method validation protocol, on template TPL-TMV-001 revision D, flagged because revision E is current. Product and requirement R-4.6, instruments VM-05 and GB-11, and the Leiden site are all read from the file.

Read on arrival. The template flag appears before any review starts.
3

Each reviewer reads all 8 pages on its own

The GxP reviewer checks references against the library. The data integrity reviewer reads data sheets and records. The test design reviewer matches requirements to limits. The writing reviewer reads for terms and numbering. Redlines land as they are found: a superseded template, a blank calibration due date, ten parts taken at random from lot 26-0412, an abbreviation nobody defined.

The panel reading. Redlines arrive column by column, and merged findings build below.
4

Two reviewers, separately, find the same missing limit

The test design reviewer writes that nothing in Table 2 shows VM-05 can tell parts apart. The GxP reviewer writes that Table 2 omits ndc of at least 5, required by SOP-QA-0112 revision D, section 6.2. They reach the same place from different directions, and the panel marks it. Merged by defect, eleven redlines become 7 findings: 2 critical, 2 major, 3 minor.

Two reviewers agree. A note above the columns records the agreement, and points to the finding.
5

F-01, with the procedure passage behind it

In the marked-up document, finding F-01 sits on page 4, in Table 2. On the right: what was found, why it matters, and the evidence. SOP-QA-0112 revision D opens at page 6, section 6.2, with the sentence highlighted, and template revision E below it asks for each limit in the table before execution. Both are the sample company's own documents, and neither quotes a regulator.

Markup and evidence. Findings by severity on the left, the document with its passages marked in the middle, the finding and its evidence on the right.
6

Dana accepts F-01, and the template finding opens next

She accepts it, and it goes into the redlined copy. F-02 opens: written on template revision D, replaced on July 1, 2026 by revision E, which added the limits table. That is why F-01 exists. The suggested edit, the reviewers who raised it and how often your people upheld findings like it sit on the same screen.

One decision at a time. A note confirms F-01 goes to Sam with the redlined copy. F-02 is open for her decision.
7

Seven findings go back to Sam, before he measures

The rest are fixes Sam can make before execution: choose parts across 9.7 to 10.3 mm from at least three lots, name the VM-05 export as the original record, measure from the distal tip as R-4.6 does, add GB-11's calibration due date. Dana returns the protocol with a message: critical items first. The return is under her name on the audit trail.

Return to the author. Returning is the reviewer's decision, recorded under her name. The markup stays advisory.
15 · The other screens

The report findings, trace matrix, checklist, document library, accuracy scores and grading rules on real screens

In shortBehind the panel sit the reconciled list, the record of what was dropped and why, a located finding for each defect, the traceability matrix, the pass or fail checklist, every open review, the library of revisions, the accuracy screens and the settings that hold your own rules. All figures are sample data.

Reconciled findings. One row per defect, with a dot under each reviewer that raised it and how often your people upheld findings like it. Every one waits for a decision.
What was dropped, and why. On the sample report: 21 redlines raised, 8 merged as duplicates, 2 dropped because the document does not support them, each with its reason.
A requirement no test covers. R-4.2.3 asks for at least 15.0 N after 2 hours at 37 °C. The test method's scope includes hydrated catheters, and section 7.1 of the report never tests them.
A statistic recomputed. Table 3 reports everything but ndc. The test design reviewer recomputes it from the table's percentages, 1.41 × (98.2 ÷ 19.0), about 7. The author still has to report it.
A correction with no explanation. Trial 2 of sample S07 struck from 21.4 N to 20.4 N with no initials, date or reason. The reviewer quotes raw data and never alters it.
The traceability matrix. Eight requirements from the specification, test method and procedure: 6 traced, 1 partly traced, 1 untraced. Flagged rows open their findings.
The checklist. Checks against the template and procedures, each failure linked to its finding. Two sit with the reviewer to check.
What the author gets. Redlined Word with tracked changes and a comment per finding, annotated PDF, findings table, checklist and matrix. Each is stamped as advisory markup, and the controlled original is unchanged.
Dismissing needs a reason. A false alarm is dismissed with a reason, under the reviewer's name, and counts toward the false-alarm measure.
Every open review. Each document with findings by severity, stage, named reviewer and due date, across three sample plants.
The revision library. Each controlled document with its effective date and earlier revisions. When SOP-MET-0031 revision E took effect, the four open reviews citing revision D were re-checked.
Accuracy against past reviews. Each reviewer's recall within its own area, false alarms and criticals missed, against 36 past reviews and 412 findings. Sample figures. The panel's critical recall counts 61 of 63, a small count: see section 11.
Scores and agreement over time. Sample monthly scores rise from April to September. Read a rising line on a fixed key with care: rules tuned on the same documents flatter it, so keep a held-out set, documents never used for tuning.
Where the panel and people differed. The misses are named: a report whose conclusion claims 95/90 (95% confidence, 90% reliability) while a scanned sheet shows a failed sample, and a statistic taken from a summary table. False alarms that changed a rule are listed beside them.
Your panel. Who sits on the panel, each with its measured recall and false alarms. A further setting says what happens when only one reviewer raises a finding.
Your rules, and who decides. Grades are your rules, and each document type has a named person. The panel's role reads Advisory only, locked: it can never approve, sign or move a document to Approved.
Two things on these screens a real reviewer would change. The sample report's F-05 corrects a catheter standard to its 2013 edition with the 2017 amendment. ISO published a 2023 edition replacing both, so your standards register should say so.17 And the sample report's 14.1% of tolerance sits on a requirement with only a lower limit, so a reviewer would ask what tolerance it divides by. Both show why a person reads the result.
16 · Reviewers and who decides

Four AI reviewers, a reconciler, a markup writer and an accuracy scorer: each one's job and the person who decides

In shortSeven agents each do one narrow job, and each has a line it never crosses. None can approve. A named quality reviewer for each document type decides every finding, with author and reviewer kept apart.

On the sample report, 21 redlines become 11 findings, and each one still waits for a person
Redlines raised by four reviewers21
Kept after re-reading the passage19
Findings after merging duplicates11
Raised by two or more reviewers7

Fictional example from this guide

Show the numbers
StageCount
Redlines raised by four reviewers21
Kept after re-reading the passage19
Findings after merging duplicates11
Raised by two or more reviewers7
Two in three sample findings had at least two reviewers behind them

Findings over 30 days in the sample data, by how many reviewers raised each.

Two reviewers: 41%One reviewer: 35%Three or four reviewers: 24%
65%2+ reviewers
  • Two reviewers41%
  • One reviewer35%
  • Three or four reviewers24%

Fictional example from this guide

Show the numbers
PartValue
Two reviewers41%
One reviewer35%
Three or four reviewers24%

One job each: what the seven agents, from GxP reviewer to accuracy scorer, do and never do

AgentWhat it doesWhat it never does
GxP reviewerReads as a quality auditor: template, required sections, and every procedure and standard against the revision in force on the first test dateApproves, or judges a revision by today's date
Data integrity reviewerChecks corrections, date format, original records, instrument IDs and calibration on the test datesAlters raw data. It quotes it.
Test design reviewerBuilds the requirement, test and result matrix both ways, checks limits, parts and samples, and recomputes GRR, ndc and capability from raw dataAccepts a reported statistic without recomputing it
Writing reviewerFinds undefined abbreviations, IDs written two ways, numbering, units and broken references, with replacement textRewrites technical content
ReconcilerGroups redlines by defect, marks agreement, re-reads each passage, drops what the document does not support and says why, and grades by your rulesKeeps a finding with no page, section and quote
Markup writerWrites the redlined Word, annotated PDF, findings table, checklist and matrixEdits the controlled original
Accuracy scorerEach night, runs the panel on your past reviews and scores recall by severity and false alarms. Blocks a panel version under your limits.Changes the answer key, which is read-only

Who writes, who decides and who owns the library: Dana, Sam, Omar, Lena and Maya

Fictional, from the sample data
DO

Dana Okafor · quality reviewer, validation

Decides findings on test method validation documents.

"Show me where the reviewers agree, and how often they've been right."
SP

Sam Patel · validation engineer

Author of TMV-0193 and TMV-0195. Gets the redlined copy.

"Tell me what to fix before I measure, and spare me the news afterward."
OH

Omar Haddad · quality manager

Owns the grading rules and the release limits, and decides design verification findings.

"No new panel version ships under 95% critical recall."
LO

Lena Ortiz · quality engineer, equipment

Decides IQ, OQ and PQ findings for two other plants.

"Half my comments are the same calibration and date errors."
MC

Maya Chen · document control

Owns the library and its effective dates.

"A revision is current on the test date, whatever today says."

Advisory, located, recorded: the controls around a finding

Enterprise controls. Role-based access, maker and checker kept apart, a named decider per document type, versioned grading rules, a dismissal that needs a reason, an audit trail of every submission, run, decision, rule change and library event, audit export, and multi-site review across plants. Your documents stay with you, and no model is trained on them. Botminds is SOC 2 Type II audited, and its information security is managed to ISO 27001.

What software cannot claim. GxP, 21 CFR Part 11 (FDA's electronic records rule) and EU GMP Annex 11 (its computerized systems chapter) cannot be certified for a product, and no product arrives validated for your use. These are controls that support your compliance. You assess Botminds as a supplier, you validate your use of it to your own procedure, and your people approve your documents.

Where the AI rules touch this. Reviewers that read documents may use large language models. Draft EU Annex 22 says such models "should not be used in critical GMP applications", and it is still a draft; EMA's 2026 workshop report shows that wording under debate.35,37 For a device maker, FDA's Computer Software Assurance guidance reaches AI tools used in the quality management system.10 The assessment of your use is yours to make and record.

17 · Inputs, outputs, targets

From protocols, templates and past reviews to located redlines: what Validation Document Review reads, returns and aims for

In shortThe solution reads the documents your review already runs on, and returns markup in the formats your authors use. Its outcome figures are design targets, to be measured on your own documents. One proof of concept is on record, and it is stated here exactly as our site states it.

Read in place

  • Validation protocols and reports: TMV, DV, IQ, OQ, PQ, in Word or PDF, executed or not
  • Product requirements and test methods
  • Document library: SOPs, specifications and standards, with every revision and its effective date
  • Calibration records

From your team

  • Controlled templates and grading rules
  • Who decides, by document type
  • Past human reviews, as the answer key
Four reviewers read separately Every finding has a page, a section and a quote
A named person decides each one
It can never approve

What comes out

  • Four columns of located redlines, agreement marked
  • Redlined Word and annotated PDF
  • Findings table by severity
  • Pass or fail checklist and traceability matrix
  • Accuracy scorecard per reviewer
  • An audit trail under named people

Document systems, validation tools and calibration records this works with, by category

It works with what you already run: a document or quality management system for controlled documents, a digital validation tool if you have one, a calibration or metrology system, and your standards register. Review stays in one place across plants, with a named decider for each document type.

14 minutes, 95% and under 10%: the design targets, and what each one counts

14 min

from upload to a marked-up document, against about 3.5 hours by hand on the sample estimate. The reviewer's own reading and decisions come on top, so time those.

Design target
95%+

of critical findings caught, scored against past human reviews.

Design target
Under 10%

of findings raised turning out to be false alarms.

Design target

Targets are design goals, measured in the live solution. The 96.8% and 7.4% on the screens are sample data. Section 22 shows how to test any of these on your own files.

The one engagement on record for this solution, as our site states it. "Proof of concept complete at a global medtech manufacturer, scored against an answer key of past human reviews." That is a proof of concept, and we add nothing to the statement. It carries no outcome figure here, and the figures on the screens are sample data. In any engagement the customer validates, the software flags and a person decides.
Part C · Are you ready to automate?

Should your plants automate validation review? What late findings cost, what software could return, and a score against your own past reviews

You run validation or quality, or you review these documents yourself. This part is written for you: the costs that hide in rework and repeat studies, a calculator, whether your library and rules are ready, what to ask any vendor of AI review software, including us, and a pilot that ends in numbers.

18 · What it costs you

Review hours, repeat studies and rework after approval: what a slow or leaky validation review costs you

In shortThree costs add up: reviewer hours you can count, studies repeated because a gap surfaced late, and findings that reach an inspector. Nobody publishes any of the three for validation review, so the only trustworthy numbers are the ones you gather in a week from your own document system.

153

process validation citations on device Form 483s in fiscal 2025, by our sum of FDA's rows.18

FDA data, before the QMSR
23

citations on drug Form 483s under 21 CFR 211.165(e), on showing test methods work.18,5

FDA data, fiscal 2025
No public figure

for review hours, escape rates or the cost of a repeat study. We looked, and these need your own measurement.

As of November 2026
Tracing, citations and template checks hold most of the hours software could shorten, by the sample estimate

Hours per report: by hand, and with markup in hand for a person who still reads and decides. The second column is our cautious placeholder, far above the 14-minute design target for producing markup. Replace both.

By hand (sample estimate)Reading with markup in hand (placeholder)
Template sections and fields0.75 hours0.1 hours
Citations at the test date0.75 hours0.15 hours
Tracing and recomputing1 hour0.4 hours
Data sheets and calibration0.5 hours0.2 hours
Terms and numbering0.25 hours0.05 hours
Writing up redlines0.25 hours0.1 hours

Illustrative · replace with your own numbers

Show the numbers
By hand (sample estimate)Reading with markup in hand (placeholder)
Template sections and fields0.75 hours0.1 hours
Citations at the test date0.75 hours0.15 hours
Tracing and recomputing1 hour0.4 hours
Data sheets and calibration0.5 hours0.2 hours
Terms and numbering0.25 hours0.05 hours
Writing up redlines0.25 hours0.1 hours

Five documents and a stopwatch: find your own review hours, rounds, repeats and late findings in a week

CostWhere it hidesHow to find your number in a week
Review hours per documentAbsorbed in a reviewer's dayTime five documents by type, with a stopwatch, by step
Waiting daysBetween submission and first commentPull dates from your document system for the last 30 documents
Review roundsRevision numbers and email threadsCount rounds per document, and read why the third one happened
Repeated studiesNew protocol numbers with similar titlesList repeats from the last two years, and the finding that caused each
Findings after approvalAudit reports and corrective actionsSearch them for citations, limits and calibration on approved documents
Reviewer disagreementNowhere, because nobody comparesHave two reviewers read one closed document apart, and compute overlap
Stale citations in open workRevisions released while reviews are openPick the last SOP revision, and count open documents citing the old one

The launch date, the good reviewer's time, the inspector's second question: costs no calculator can price

A launch waiting on one signatureA method awaiting approval can hold up a design transfer, the handover of a design to production. Its value depends on the product, so we leave it out.
Your best reviewer's attentionAn expert who spends the morning on date formats spends less of it on whether the test design works.
The inspector's second questionOne out-of-date citation invites a look at how many others exist. The first answer decides how long that lasts.
Engineers learning the rules lateA redline after a study teaches the same lesson as one before it, at a far higher price and with worse morale.
Plants drifting apartReviewers at three sites apply three versions of one rule, and a merged quality system exposes it.
19 · Your return

Your return on AI-assisted validation review: reviewer hours, fewer repeat studies, and what stays unpriced

In shortEnter your own numbers. Hours are the part you can defend quickly. Repeat studies avoided are worth more, and you need your own history to claim any. The calculator keeps a person reading every document, so it starts from a saving far below what a vendor's headline would suggest.

Clerical hours, review rounds, repeat studies: the formulas behind a validation review saving

The hours

Clerical checks done first

Citations, template fields and recomputation arrive done, for a person to confirm.

documents × (hours by hand − hours with markup) × hourly cost
The rounds

Fewer trips back

Authors get one complete list, with the critical items first.

documents × rounds avoided × hours per round × hourly cost
The repeats

Gaps caught in the protocol

A missing limit or poor part selection found before anyone measures.

repeat studies avoided × cost per repeat
The wait

Earlier approval

Real for the program, and left out of the calculator because its value varies by product.

days earlier × value per day of the launch or change
The consistency

One rule across plants

The same grading rules read the same way at every site. Real, and left out.

findings graded differently ÷ all findings, before and after
The evidence

A measured review

You can say how your review performs. Real, and left out.

recall and false alarms, by severity, on a held-out set

Put in your own document count: reviewer hours freed and repeat studies avoided

3.5 hours is the sample estimate for one report by hand. Every other default is a placeholder, and we hold the with-markup hours well above the 14-minute design target because a person still reads and decides.

Review work
Repeat studies
Cost
Illustrative yearly value
Reviewer hours freed0
Hours freed, valued$0
Repeat studies avoided, valued$0
After the yearly cost$0

Formula: documents × (hours by hand − hours with markup) × hourly cost + (repeats today − repeats after) × cost per repeat − yearly cost. Hours freed are capacity you can redirect, and they become money only if you redirect them. Set the two repeat figures equal if you have no history to support a change.

20 · Readiness check

From a dated document library to an answer key you trust: eight questions that score your validation review

In shortAnswer honestly, 0 to 2 on each. Your score suggests whether to fix your library and rules first, run a pilot on past reviews, or plan a rollout.

1
A library with effective dates

Can you look up every SOP, template and standard, with each revision's effective date, in one place?

Why it mattersAny check of a citation by date depends on this, for people and for software.
A strong answer"Yes, including external standards, with one named owner."
2
A written date rule

Does a procedure say which date decides whether a revision applies, and how a transition works?

Why it mattersWithout one, two reviewers can both be right and still disagree.
A strong answer"First test date, with a stated transition for work under way."
3
Written grading rules

Could a new reviewer tell critical from major from minor by reading your rules?

Why it mattersA tool can only grade by rules someone wrote down, and people need them too.
A strong answer"Yes, with examples, and changes go through change control."
4
Current labels after the QMSR

Have your templates and checklists moved from 21 CFR 820.30, .72 and .75 to the ISO 13485 clauses, if you make devices?

Why it mattersFDA's 2026 letters cite the clauses. Old labels in new documents look like nobody read the rule.
A strong answer"Done, or not applicable, with old records left as they stand."
5
Past reviews you could use as a key

Do you have 30 or more closed reviews with their findings, signed off, in a form someone can extract?

Why it mattersThis is how you would test any reviewer, human or software, on your own work.
A strong answer"Yes, by document type, with severity recorded."
6
A baseline in hours and rounds

Do you know hours per document, rounds and repeat studies, by document type?

Why it mattersWithout one, no vendor's number means anything, including ours.
A strong answer"Five documents timed by step, and two years of repeats listed."
7
Who decides, and how much they read

Have you named a decider per document type, and said what they must still read when flags arrive?

Why it mattersA person who reads only flags inherits every miss.
A strong answer"Named people, a reading rule, and sampling of unflagged pages."
8
Ready to assess an AI tool

Do quality and IT know how they would assess a tool that reads GxP documents, and have they read the relevant guidance?

Why it mattersYou validate your use of the tool, and record your reasoning under FDA's software guidance or draft Annex 22.
A strong answer"Intended use drafted, risk assessed, and acceptance scores set in advance."
9
The hours you get back · for reflection

If your reviewers no longer checked dates and numbering, where should their attention go: whether the test design works, whether conclusions follow, reviewing the reviewers, or coaching authors? Not scored.

Date your library first: what a score of 0–6, 7–11 or 12–16 asks you to do next

0–6

Explore

Date your library, write the date rule and grading rules, move to current labels and time five reviews. All of this pays off before any software arrives.

7–11

Ready to pilot

Extract past reviews as a key, keep some aside, score a tool blind against your people's findings, and then read one live document with it.

12–16

Ready to implement

Plan connections to your document system, grading rules by plant, deciders, your assessment of the supplier and your validation of your use.

21 · Questions for any vendor

Measured accuracy, located findings, who approves, compliance claims: questions that test an AI validation review vendor

In shortAsk every vendor the same questions, us included. The answers show whether the tool can be scored on your own documents, whether each finding can be checked, whether it could ever approve, and how honest the claims are.

AskA good answerA warning sign
Measured accuracy
What is your recall on critical findings, on whose documents, and how many?A count, the document types and the method, with a test on yoursA percentage with no count
How wide is the uncertainty on that number?An interval, stated unpromptedA bare percentage, as if exact
Do you keep a held-out set that rules were never tuned on?Yes, and you hold itScores only on the tuning set
What do you mean by a false positive?A clear definition, and who judged each oneDismissals unexamined
Which misses do you know about?Named, with what changed afterward"We rarely miss"
Each finding
Can I open every finding at its page, passage and source?Yes, in one click, and unsupported ones are dropped with a reasonA summary with no location
Which date does it use to judge a revision?Your rule, configurable"The latest version"
Does it recompute statistics from raw data, including scanned sheets?Yes, and it shows the working and its confidenceIt reads the reported figure
People and approval
Can the tool ever approve, sign or change status?No, and they show you the lock"With a setting"
How do you keep a reviewer reading?Planted defects, sampling, and showing why a finding existsOnly an "accept all" button
Does it edit the controlled original?Never. It works on a copy, stamped as advisory.Edits in place
Compliance claims and AI
Is your product validated, Part 11 compliant or GxP certified?No product can be for your use. Here are the controls, and here is what you validate."Pre-validated and fully compliant"
Which steps use a language model, and how would I assess that?A step-by-step map, and your own risk call under FDA's software guidance or draft Annex 22"AI handles it"
Are my documents used to train a model?No, in writingA vague policy link
What security credentials do you hold?Named audits and reports, which you can readLogos with no report
Proof and scale
Where has this run, at what stage?The honest stage: pilot, proof of concept or production. Ours is a proof of concept at a global medtech manufacturer, scored against an answer key of past human reviews."Deployed widely", with no detail
How does it handle many plants, each with its own rules and languages?Rules and deciders per plant, shown on your second siteOne global rule set
22 · A pilot on past reviews

A blind pilot for validation review: score the tool on closed documents, then read one live protocol with it

In shortPull closed reviews and set some aside. Agree on the scores you need before you see any result, the same discipline you ask of a protocol. Score the tool blind against your people's findings, check a sample of its "false alarms" by hand, then run live documents with a person deciding. Decide on the numbers below.

  1. Weeks 0 to 2. Write the pilot's own protocol: what you will test, your acceptance limits and who judges. Assess the tool as a supplier. Time five reviews for a baseline.
  2. Weeks 2 to 4. Extract 30 or more closed reviews with findings and severity. Keep about a third aside, unseen. Load your library, templates and rules.
  3. Weeks 4 to 6. Run the tool on the working set, and tune rules openly. Run it once on the held-out set, and stop tuning.
  4. Weeks 6 to 7. Check by hand a sample of its findings your people never raised. Some will be false alarms, and some will be real defects your review missed.
  5. Weeks 7 to 10. Read live documents with people deciding each finding, timed. Plant a known defect in a few. Show the record to an auditor who was not involved, and write down why you decided as you did.
Ten weeks from a written pilot protocol to a decision built on a held-out score
Your teamWith the vendor
Write limits; assess supplier; time five reviews
Extract past reviews; hold some aside
Load library and rules
Tune on the working set, then one held-out run
Check unmatched findings by hand
Live documents, timed, with planted defects
Decide, and record why
Week 0246810

Illustrative · replace with your own numbers

Show the numbers
ActivityFromTo
Write limits; assess supplier; time five reviews02
Extract past reviews; hold some aside24
Load library and rules24
Tune on the working set, then one held-out run46
Check unmatched findings by hand67
Live documents, timed, with planted defects79.5
Decide, and record why9.510

Held-out recall, false alarms, new defects and reviewer hours: the numbers on this pilot's scoreboard

MeasureHowWhy
Critical recall on the held-out setHits ÷ criticals in the key, with its intervalThis is the failure that matters most, and the interval keeps you honest
False alarms, after your checkUnsupported ÷ raised, judged by a personToo many, and reviewers stop reading
New real defectsFindings your review missed, upheld by a senior reviewerThe part of the value no answer key can show
Citation validityOpen 100 citations. Does the passage say it, at that revision?A wrong pointer is worse than none
Planted defects caught by peoplePlant a few the tool cannot see. Do people catch them?It shows whether people are still reading
Hours and roundsStopwatch by step, and rounds per document, against your baselineYour baseline, since no public one exists
Deep questions to settle before you scale

Your date rule. Does it hold for a protocol approved under one revision and executed under the next?

Single-reviewer findings. Do you keep them, drop them or ask for a second read? Single readers often catch what others cannot, so a rule that drops them trades recall for tidiness.

Grading changes. When someone tightens a rule, does the key get re-scored, and who approves it?

Language. If some plants write in another language, how will you score each language on its own?

Skills. If juniors no longer do the clerical checks, how do they learn what a good protocol looks like?

Audit answers. How will you explain to an inspector what the tool does and who decides? Practice that before an inspector asks.

23 · Questions people ask

Protocols, IQ OQ PQ, ndc, acceptance criteria, the QMSR and AI reviewers: what people ask about validation review

In shortShort answers to what quality and validation teams search for, each one complete on its own. Rules and statuses are as of November 2026.

What is validation document review?

Validation document review is the check a qualified person makes on a validation protocol before it runs, and on its report afterward. The reviewer compares the document with its template, the procedures in force, the requirements and the raw data, then returns located corrections. Only a document that passes is approved and relied on.

What should a reviewer check in a validation protocol?

A reviewer checks that the protocol is on the current template, cites the procedures in force and states every required limit before the study runs. The reviewer also checks that parts and samples are chosen on purpose, each requirement reaches a test, and the original record is named. A flaw caught here costs a sentence to fix, and the same flaw in a report can cost a repeat study.

What is the difference between a validation protocol and a validation report?

A protocol is written and approved first. It states what will be done, on what, and which results count as a pass. A report comes after and states what happened, how results compare with each limit, what deviated and what the study concludes. EU GMP Annex 15 asks for results summarized against the acceptance criteria.

What do IQ, OQ and PQ mean?

Installation qualification shows equipment is installed as specified. Operational qualification shows it works as designed, including upper and lower limits or worst cases. Performance qualification shows it performs under normal operating conditions with production materials or a proven stand-in. EU GMP Annex 15 describes all three, and they may sometimes be combined.

Can acceptance criteria be changed after a validation protocol is approved?

Yes, with a burden of proof. EU GMP Annex 15 says significant changes to the approved protocol during execution, including acceptance criteria, should be documented as a deviation and scientifically justified. FDA's process validation guidance says departures must be justified and approved before implementation. A limit changed once results are visible will always draw questions.

What is test method validation?

Test method validation shows that a measurement can be trusted for its use. Device makers commonly use gage repeatability and reproducibility studies for variable data. For drugs, 21 CFR 211.165(e) asks that the accuracy, sensitivity, specificity and reproducibility of test methods be established and documented, and ICH Q2(R2) covers analytical procedures.

What is a good ndc in a gage R&R study?

The number of distinct categories should usually be 5 or more, which the statistics software maker Minitab reports as the recommendation of the AIAG automotive manual. It equals 1.41 times part standard deviation divided by gage standard deviation, truncated. It depends on the parts chosen, so a study on parts from one lot can score low on a good measuring tool. Write the part selection into the protocol.

What replaced 21 CFR 820.30, 820.72 and 820.75?

FDA's Quality Management System Regulation took effect February 2, 2026 and incorporates ISO 13485:2016 by reference. Design verification and validation now fall under clauses 7.3.6 and 7.3.7, process validation under 7.5.6 and monitoring and measuring equipment under 7.6. FDA's 2026 warning letters cite ISO 13485 clauses directly, such as 7.6 and 7.3.1.

Which revision of a procedure applies to a validation study?

The one your quality system says applies, which is most often the revision in force on the first test date. We found no regulator that fixes this date, so write it into a procedure, along with how work under way transitions. A reviewer then checks each citation against that date and looks at what changed between revisions.

What does ALCOA mean in validation documents?

In FDA's data integrity guidance, ALCOA means data that are attributable, legible, contemporaneously recorded, original or a true copy, and accurate. The UK regulator MHRA adds that ALCOA+ brings in complete, consistent, enduring and available. In a validation report, this means explained corrections, readings that match their first capture, and original records that still exist.

Can AI review validation documents?

Software can read a document and flag located defects, and a qualified person should decide each one. FDA's February 2026 Computer Software Assurance guidance reaches AI tools used in a device maker's quality management system. Draft EU GMP Annex 22 says large language models should not be used in critical GMP applications, and EMA's 2026 workshop shows that wording under debate. The draft is not final.

Can validation review software be validated or GxP certified?

No product can be certified for GxP, Part 11 or Annex 11, and no product arrives validated for your use. The regulated company validates its own intended use. A supplier can offer evidence and controls that support your compliance, such as audit trails, role separation and located, recorded decisions.

How do you measure whether a validation reviewer is accurate?

Take past documents with signed-off findings as an answer key. Recall is the share of the key the reviewer finds, by severity. The false-alarm rate is the share of what it raises that is not upheld. Report the count and its interval, keep some documents aside from any tuning, and check a sample of unmatched findings by hand, since the key contains human misses.

How long should a validation document review take?

We found no public benchmark. One sample estimate puts a test method validation report at about 3.5 hours by hand, and yours will differ by document type and length. Time five documents by step, count the review rounds, and treat that as your baseline before believing any vendor's figure.

24 · One-page summary

One page to print: the eight checks of a validation review, the rules as of November 2026 and 14 terms

Print this page

In shortThe whole guide on one screen: what to check, the rules as of November 2026, the readiness bands and the terms.

The checks
  1. Right template, at the current revision, with every section and field.
  2. Every citation against its effective date and the first test date, by your written rule.
  3. Every limit the procedure demands, stated before execution.
  4. Parts and samples chosen on purpose, with a reason for the size.
  5. Each requirement to a test and result, and each test back.
  6. Statistics recomputed from raw data.
  7. Corrections explained, original record named, instruments in calibration on the day.
  8. A conclusion that follows from the results, in words a stranger can read.

Readiness: score 0–2 on eight questions: 0–6 explore · 7–11 pilot · 12–16 implement.

As of November 2026: QMSR in effect February 2, 2026, ISO 13485:2016 by reference · FDA software guidance final, February 3, 2026, device production and quality management systems · 21 CFR Part 211 for drugs · EU GMP Annex 15 as of October 1, 2015, with a draft amendment due December 2026 and publication planned for April 2028 · Annex 22 a draft · FDA's AI guidance a draft · AI Omnibus in force July 27, 2026.

14 terms
Validation
Documented proof that a process, method or piece of equipment does its job.
Protocol
The pre-approved plan and limits for a validation study.
Report
What happened, against each limit, with a conclusion.
IQ, OQ, PQ
Installation, operational and performance qualification.
TMV
Test method validation: showing a measurement can be trusted.
DV
Design verification: showing a design meets its input requirements.
Acceptance criterion
A limit set before the study.
Redline
A located correction. A finding is the defect behind it.
GRR
Gage repeatability and reproducibility: variation from the measuring itself.
ndc
Number of distinct categories a method can tell apart.
ALCOA+
Attributable, legible, contemporaneous, original, accurate, and complete, consistent, enduring, available.
QMSR
FDA's Quality Management System Regulation, in effect February 2, 2026.
Recall
The share of known findings a reviewer finds.
Answer key
Past reviews with signed-off findings, used to score a reviewer.
25 · Sources

Sources

Accessed November 2026. Regulatory status statements are as of November 2026. FDA warning letters are cited from FDA's own copies, for what each one says. ISO and AIAG texts are sold: where we read a summary, the source line says so. Studies from other fields are labeled as such.

  1. FDA, "Quality Management System Regulation (QMSR)": effective February 2, 2026; FDA stopped using QSIT and began using Compliance Program 7382.850 that day. Read November 3, 2026. fda.gov
  2. FDA warning letter 730215, Linemaster Switch Corporation, May 27, 2026, item 5, citing ISO 13485:2016 clause 7.6. fda.gov
  3. European Commission, EudraLex Volume 4, Annex 15, "Qualification and Validation", in operation since October 1, 2015, sections 2.2 to 2.10, 3.8 to 3.13, 5.21 and 9. health.ec.europa.eu
  4. Minitab, "Using the number of distinct categories in a gage R&R study": ndc is 1.41 times part over gage standard deviation, truncated; reports AIAG's recommendation of 5 or more. We read Minitab's account of the AIAG manual, not the manual itself, which is sold. support.minitab.com
  5. 21 CFR 211.165(e), 2025 edition, on establishing and documenting the accuracy, sensitivity, specificity and reproducibility of test methods. govinfo.gov
  6. Efor Group, "Design and development management of a MD/IVDMD according to EN ISO 13485:2016", a consultancy's summary of clauses 7.3.6 and 7.3.7. We read this summary and FDA's letters, not ISO's own text, which is sold. efor-group.com
  7. FDA, "Process Validation: General Principles and Practices", guidance, January 2011, section on the process performance qualification protocol and report. For drugs and biologics; nonbinding. fda.gov
  8. European Medicines Agency and PIC/S, concept paper on the revision of Annex 15, EMA/INS/GMP/163466/2026, consultation February 9 to April 9, 2026; timetable: draft for consultation December 2026, comments to March 2027, inspectors' group endorsement November 2027, Commission publication and PIC/S adoption April 2028. ema.europa.eu. It overtakes the Q4 2026 target for Annex 15 in the inspectors' 2026 to 2028 work plan.
  9. FDA, "Medical Devices; Quality System Regulation Amendments", final rule, 89 FR 7496, February 2, 2024: incorporates ISO 13485:2016 by reference; sections 820.20 to 820.30 and 820.40 and Subparts C to O, which held 820.72 and 820.75, reserved. govinfo.gov
  10. FDA, "Computer Software Assurance for Production and Quality Management System Software", final guidance, February 3, 2026; scope is computers and automated data processing systems used in medical device production or the quality management system. Nonbinding. fda.gov
  11. European Commission, EudraLex Volume 4 page, read November 3, 2026: Annex 15 as in operation since October 1, 2015; Annex 11 at its January 2011 revision; no Annex 22. health.ec.europa.eu
  12. FDA, ICH "Q2(R2) Validation of Analytical Procedures", final guidance, March 2024, docket FDA-2022-D-1503. fda.gov
  13. FDA, Compliance Program 7382.850, Inspection of Medical Device Manufacturers, implementation date February 2, 2026: its table of requirements lists Clause 7.3.6, Clause 7.3.7, Clause 7.5.6, Clause 7.6 and, for documents and records, Clauses 4.2.1, 4.2.4 and 4.2.5. fda.gov
  14. FDA warning letter 738562, Unilam Co., Ltd., September 22, 2026, item 2, citing ISO 13485:2016 clause 7.3.1. fda.gov
  15. 21 CFR 211.100(a), 2025 edition, on written production and process control procedures, reviewed and approved by the quality control unit. govinfo.gov
  16. 21 CFR 211.194(a)(2), 2025 edition, on showing that test methods meet proper standards of accuracy and reliability. govinfo.gov
  17. Swedish Institute for Standards, listing for ISO 10555-1:2023: edition 3, replaces ISO 10555-1:2013 and Amd 1:2017. sis.se
  18. FDA, Inspection Observations, fiscal years 2018 to 2025 spreadsheets. Sums of rows, and rates per 100 forms from each file's Summary sheet, are ours. FDA says the files are not the complete set of Form 483s; fiscal 2025 covers inspections ending October 1, 2024 to September 30, 2025, before the QMSR. fda.gov
  19. Minitab, "Key results" for a crossed gage R&R study: AIAG guideline, under 10% of process variation. support.minitab.com
  20. Fred Schenkelberg, "Sample Size – Success Testing", Accendo Reliability, December 29, 2011, modified March 2, 2024: the success run formula, and why it no longer applies after a failure. accendoreliability.com
  21. FDA, "Data Integrity and Compliance With Drug CGMP: Questions and Answers", final guidance, December 2018. fda.gov
  22. MHRA, "GXP Data Integrity Guidance and Definitions", revision 1, March 2018, sections 3.10, 4.3 and 6.15. gov.uk
  23. PIC/S, PI 041-1, "Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments", July 1, 2021. picscheme.org
  24. 21 CFR 211.160(b)(4), 2025 edition, on calibration at suitable intervals. govinfo.gov
  25. FDA warning letter 707614, Microspecialties, LLC, May 8, 2025. fda.gov
  26. FDA warning letter 662115, Caltag Medsystems Ltd, August 31, 2023. fda.gov
  27. FDA warning letter 717456, Tower Laboratories Ltd., December 23, 2025. fda.gov
  28. Bornmann, Mutz, Daniel, "A reliability-generalization study of journal peer reviews", PLoS One 2010;5(12):e14331: 48 studies, 19,443 manuscripts. Abstract read. Journal manuscripts, not validation documents. pubmed
  29. Laitenberger, Atkinson, Schlich, El-Emam, "An experimental comparison of reading techniques for defect detection in UML design documents", National Research Council Canada, ERB-1069, December 1999: 18 practitioners. ehealthinformation.ca
  30. Basili et al., "The empirical investigation of Perspective-Based Reading", Empirical Software Engineering 1996;1(2):133-164. Abstract read. Software requirements documents. link.springer.com
  31. Maldonado, Carver, Shull et al., "Perspective-based reading: a replicated experiment", Empirical Software Engineering 2006. Abstract read. link.springer.com
  32. Petersson, Thelin, Runeson, Wohlin, "Capture-recapture in software inspections after 10 years research", Journal of Systems and Software 2004;72(2):249-264. Catalog abstract read. lunduniversity.lu.se
  33. Wohlin, Runeson, Brantestam, "An experimental evaluation of capture-recapture in software inspections", 1995. Catalog abstract read: the assumptions are not fully met, leading to underestimates. research.lu.se
  34. NIST/SEMATECH e-Handbook of Statistical Methods, section 7.2.4.1, confidence intervals for a proportion. nist.gov
  35. European Commission and PIC/S, draft Annex 22: Artificial Intelligence, consultation July 7 to October 7, 2025, sections 1, 6 and 10.5. A draft, not in force. picscheme.org
  36. FDA warning letter 722591, Purolea Cosmetics Lab, April 2, 2026, on AI-generated documents and 21 CFR 211.22(c). One firm, with other findings. fda.gov
  37. European Medicines Agency, report of the multistakeholder workshop of June 30, 2026 on Annex 22, EMA/156789/2026. ema.europa.eu
  38. FDA, "Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products", draft guidance, January 2025, docket FDA-2024-D-4689. Still a draft. fda.gov
  39. European Medicines Agency, reflection paper on the use of artificial intelligence in the medicinal product lifecycle, final version adopted by CHMP September 9, 2024, and by CVMP September 11, 2024. ema.europa.eu
  40. European Medicines Agency, "EMA and FDA set common principles for AI in medicine development", January 14, 2026. ema.europa.eu
  41. European Commission, AI Act page, on Regulation (EU) 2026/1744: in force July 27, 2026; Annex III rules December 2, 2027; Annex I rules August 2, 2028. digital-strategy.ec.europa.eu
  42. ISPE, GAMP Guide: Artificial Intelligence, July 2025. ispe.org
  43. European Commission, stakeholders' consultation on EudraLex Volume 4, Chapter 4, Annex 11 and new Annex 22, July 7 to October 7, 2025. health.ec.europa.eu
  44. Goddard, Roudsari, Wyatt, "Automation bias: a systematic review of frequency, effect mediators, and mitigators", JAMIA 2012;19(1):121-127. Abstract read. Mainly clinical decision support. pubmed
  45. "2026 State of Validation Report", sponsored content from Kneat in ISPE's Pharmaceutical Engineering, July 1, 2026, 614 professionals. Kneat sells validation software; ISPE says it did not review or endorse the piece. ispe.org
  46. FDA, Report on the State of Pharmaceutical Quality, fiscal year 2025, dated June 25, 2026: 1,248 drug quality assurance inspections. fda.gov
Next step

See it on your own closed protocols and reports.

Explore the solution, or bring a set of past reviews your quality reviewers signed off. We will run the reviewers on them and score every finding against your people's, and you hold the answer key.

botminds.ai The complete guide to validation document review · November 2026. Dravenzo, Talvoren, Veltrimab, Plant 3 Leiden, every person, document number, requirement and figure in the example and the screens are fictional. Regulatory status is as of November 2026; check the sources before relying on it. This guide is general information and is not legal advice. Software cannot itself be validated for your use, GxP compliant or certified: it can carry controls that support your compliance, and you validate your use of it.